Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

This study is testing a drug called xaluritamig — a bispecific antibody that helps immune cells target and kill prostate cancer cells — in combination with hormone-blocking treatments in men with metastatic hormone-sensitive prostate cancer (cancer that has spread but still responds to hormone therapy). **You may be eligible if...** - You are a man with prostate cancer confirmed by biopsy - Your cancer has spread to other parts of the body (metastatic) and was recently diagnosed as hormone-sensitive (still responding to androgen deprivation therapy) - You started hormone-blocking therapy no more than 12 weeks before the study screening - You meet organ function and health status requirements **You may NOT be eligible if...** - Your prostate cancer has a neuroendocrine component - You have previously been treated with docetaxel chemotherapy for prostate cancer - You have significant heart disease or active serious infections - You have had prior treatment with certain immunotherapy drugs - You are unable to follow the study schedule Talk to your doctor to see if this trial is right for you.